Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Interpreting Key Trials

JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?

Mehdi H. Shishehbor, DO, MPH and Stanley L. Hazen, MD, PhD
Cleveland Clinic Journal of Medicine January 2009, 76 (1) 37-44; DOI: https://doi.org/10.3949/ccjm.75a.08105
Mehdi H. Shishehbor
National Institutes of Health CTSA-KL2 Scholar, Department of Interventional Cardiology, Heart and Vascular Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley L. Hazen
Head, Section for Preventive Cardiology and Rehabilitation
Director, Center for Cardiovascular Diagnostics and Prevention
Department of Cell Biology
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) (N Engl J Med 2008; 359:2195–2207) compared rosuvastatin (Crestor) 20 mg daily vs placebo in apparently healthy people who had levels of low-density lipoprotein cholesterol (LDL-C) lower than 130 mg/dL but elevated levels (≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50% and hs-CRP levels by 37%, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. In absolute terms, 95 people had to be treated over 2 years to prevent one event. There was, however, a higher incidence of diabetes in the rosuvastatin group.

Footnotes

  • ↵* Dr. Hazen has received fees as a consultant or speaker for AstraZeneca, BG Medicine, Biophysical, Merck, Merck/Schering-Plough, Pfizer, PrognostiX, and Wyeth Pharmaceuticals corporations. He has the right to receive royalty payments for inventions or discoveries related to Abbott Laboratories, Biosite, Frantz Biomarkers, and Siemens corporations. And he may receive future financial benefits from Cleveland Clinic for inventions or discoveries related to PrognostiX corporation.

  • Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 76 (1)
Cleveland Clinic Journal of Medicine
Vol. 76, Issue 1
1 Jan 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Mehdi H. Shishehbor, Stanley L. Hazen
Cleveland Clinic Journal of Medicine Jan 2009, 76 (1) 37-44; DOI: 10.3949/ccjm.75a.08105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Mehdi H. Shishehbor, Stanley L. Hazen
Cleveland Clinic Journal of Medicine Jan 2009, 76 (1) 37-44; DOI: 10.3949/ccjm.75a.08105
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Update in perioperative cardiac medicine 2021
  • The role of ISCHEMIA in stable ischemic heart disease
  • Renal denervation: What happened, and why?
Show more Interpreting Key Trials

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire